President Donald Trump signed an executive order to accelerate federal research into psychedelic drugs for treating mental health disorders [1].
This move marks a significant shift in U.S. drug policy by potentially opening the door for clinical applications of substances previously restricted by federal law. The administration aims to expand treatment options for those suffering from treatment-resistant conditions, with a specific focus on the veteran population.
The order focuses on the review and study of substances such as psilocybin and ibogaine to treat conditions including depression and post-traumatic stress disorder (PTSD) [1, 3]. The directive seeks to reduce federal barriers that have historically hindered the study of these compounds in clinical settings [3].
Reports said the order eases restrictions on psychedelic drugs like ibogaine to spur research on using them for medical purposes [3]. This acceleration is intended to benefit Americans, especially veterans, living with chronic mental health conditions [2].
While most sources report the signing occurred on April 18, 2026 [1, 2, 5], some reports place the date on April 17, 2026 [4]. The signing took place at the White House in Washington, D.C. [3, 5].
During the proceedings, President Trump asked, "Can I have some, please?" [1].
The administration said that the goal is to determine the efficacy of these treatments through rigorous federal review [1, 3]. By fast-tracking the research process, the government hopes to provide faster relief to those who do not respond to traditional psychiatric medications [2, 3].
“"The order eases restrictions on psychedelic drugs like ibogaine to spur research on using them for medical purposes."”
This executive order signals a transition toward a more permissive federal approach to controlled substances when used for therapeutic purposes. By prioritizing veterans and those with PTSD, the U.S. government is acknowledging the limitations of current mental health protocols and attempting to integrate psychedelic-assisted therapy into the federal healthcare framework.
